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Abstract 
Background: The pro-oncogenic transcription factor STAT3 is constitutively active 
in many tumours of different origin that often become addicted to its activity. STAT3 
is believed to contribute to the initial survival of the pre-cancerous cells as well as to 
hyper-proliferation and, later, metastasis.  
Materials and Methods: In order to evaluate the contribution of enhanced STAT3 
activation in a controlled model system, we generated knock/in mice where a mutant 
constitutively active Stat3C allele replaces the endogenous wild type allele, and 
analyzed its contribution to breast tumorigenesis. Moreover, we generated Stat3C/C 
MEF cells and analyzed their gene expression and metabolic profiles. 
Results: Constitutively active STAT3 could enhance the tumorigenic power of the rat 
Neu oncogene in MMTV-Neu transgenic mice, triggering the production of earlier 
onset and more invasive mammary tumours. Tumour-derived cell lines displayed 
higher migrating, invading and metastatic ability and showed disrupted distribution of 
cell-cell junction markers mediated by STAT3-dependent over-expression of the C-
Terminal Tensin-like (Cten) focal adhesion protein. Moreover, STAT3C alone was 
able to induce aerobic glycolysis and down-regulate mitochondrial activity both in 
primary fibroblasts and in STAT3-dependent tumour cell lines, acting via both HIF-
1α-dependent and independent mechanisms. 
Conclusions: Thus STAT3 can induce a metabolic switch which predisposes cells to 
aberrant survival, enhanced proliferation and finally tumour transformation. Later, 
enhanced Cten expression contributes to tissue infiltration and metastasis. While not 
excluding the contribution of many other tumour-specific STAT3 target genes, our 
data provide a unifying explanation of several pro-oncogenic STAT3 activities.  
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Introduction 
 
 STAT3, a member of the Signal Transducers and Activators of Transcription 
(STAT) family, is constitutively activated by phosphorylation on tyrosine 705 (Y-P) 
in a high percentage of tumours and tumour-derived cell lines of both liquid and solid 
origin. This factor is activated downstream of cytokines, growth factors and 
oncogenes including c-Src, EGFR and ErbB-2 (1). STAT3 can also be phosphorylated 
on Serine 727 (S-P) upon a number of stimuli leading to the activation of MAP 
kinases including RAS signalling (2). Tumour cells often become addicted to STAT3, 
as interference with its transcriptional activity often triggers growth arrest and/or cell 
death. Indeed, STAT3 is required for cell transformation downstream of several 
oncogenes, the prototype being v-Src (3), which triggers STAT3 Y-P. Recently, S-P 
induced by activated RAS was shown to trigger tumour transformation, driving 
STAT3 to localize to mitochondria and regulate cellular respiration (4, 5). This non 
canonical activity is required for RAS-dependent oncogenic transformation. Thus, 
STAT3 appears to exert a central role in mediating tumour transformation 
downstream of many different oncogenes and growth factors, via both canonical 
transcriptional functions and non-canonical, non-nuclear activities. 
 The pro-oncogenic role of STAT3 in vivo is underlined by the ability of its 
constitutively active mutant form STAT3C (6) to enhance malignant progression of 
skin tumours or to trigger the onset of lung adenocarcinomas (7) when overexpressed. 
STAT3 can contribute to tumorigenesis by enhancing tumour cell proliferation and 
survival, down-modulating anti-tumour immune responses, promoting angiogenesis 
and inducing cell movement and epithelial to mesenchymal transition (EMT) (8). 
Moreover, it is considered one of the main factors mediating inflammation-induced 
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cancer downstream of autocrine or paracrine production of IL-6 (9). The mechanisms 
underlying in vivo STAT3 pro-oncogenic activities and the addiction of tumour cells 
are however still incompletely understood. STAT3-mediated gene expression 
signature varies in different tumour types, and many of its known pro-proliferative or 
anti-apoptotic target genes have been identified upon acute stimulation and are not 
consistently induced in tumours displaying lower but continuous STAT3 Y-P, 
suggesting distinct subsets of target genes.  
 We have recently generated knock-in mice where a mutant Stat3C allele 
replaces the wild type endogenous gene (10). These mice display low, but continuous 
STAT3 activity, reminiscent of what observed in most STAT3-dependent tumour 
cells, and represent a good model to assess STAT3 in vivo pro-oncogenic activities. 
Here we present and discuss some of the most significant results. In particular, we 
show that STAT3 enhances tumour cell motility and invasion via a novel target gene, 
Cten, which represents a point of convergence with EGFR/HER2 signalling. 
Moreover, we discuss data showing that STAT3 acts as a master regulator of glucose 
metabolism and cellular respiration, and that its inhibition leads to apoptotic death of 
STAT3-dependent cancer cells at least partly via modifying their metabolic 
requirements (11).  
 
Results 
 
Stat3C mice display constitutive STAT3 nuclear localization, Y-P and 
transcriptional activity.  
 The Stat3C allele was expressed at physiological levels in all tissues analyzed 
(10). Stat3C/C mice died at young age upon developing auto-immune myocarditis 
(A.C. and V.P., manuscript in preparation), while heterozygous Stat3C/WT mice were 
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viable and fertile. STAT3C was indeed weekly constitutively active, showing slightly 
enhanced nuclear localization, Y-P and transcriptional activity in several tissues. 
Moreover, Y-P and nuclear localization were prolonged in mouse embryonic 
fibroblasts (MEFs) or in the liver of Stat3C/C mice upon LPS or IL-6 treatment, 
respectively (10). Both transcriptional activity and DNA binding affinity of the 
STAT3C protein were comparable to those of the wild type form, as judged by similar 
induction levels of tested target genes and by EMSA competitions (not shown). The 
slightly increased basal activity of STAT3C and its prolonged activation upon 
cytokine stimulation suggest a lower activation threshold and  represent an ideal 
model to investigate STAT3 oncogenic functions in vivo. 
 
STAT3C expression enhances Neu mediated mammary gland tumorigenesis. 
Spontaneous tumour onset could not be assessed in ageing Stat3C/C mice due to their 
early mortality. No preneoplastic lesions or spontaneously arising tumours were 
detected in heterozygous Stat3C/WT mice up to 24 months of age, and mammary gland 
morphology was normal in virgin, pregnant and lactating Stat3C/WT female mice (I.B. 
and V.P., unpublished results). We decided therefore to assess in heterozygosity 
potential cooperation with the Neu oncogene in mammary tumorigenesis. MMTV-
Neu transgenic mice (NeuT), which develop multiple foci of atypical hyperplasia 
progressing to invasive metastasizing carcinoma by 22-27 weeks, were intercrossed 
with Stat3C/WT mice to obtain NeuT, Stat3C/WT (N-C) or NeuT, Stat3WT/WT (N-WT) 
mice (10). N-C mice developed palpable tumours significantly earlier than their N-
WT control littermates (Fig. 1A, p=0.0014). N-C tumours showed normal 
proliferation rates as assessed by PCNA staining, but sensibly reduced TUNEL-
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positive apoptotic nuclei (not shown). The main biochemical pathways involved in 
Neu-mediated mammary tumorigenesis were unaffected (data not shown). 
Three independent cell lines were derived from tumours of each genotype and 
named C or WT 1, 2 or 3. All three C cell lines displayed increased nuclear, 
phosphorylated STAT3, suggesting enhanced activity of the Stat3C allele. However, 
no significant differences were detected in Pten, Akt, Gsk3-β, Src and Erk expression 
or activation levels (not shown). Likewise, C and WT cell lines did not differ 
significantly in terms of proliferation or resistance to starvation-mediated apoptosis 
(data not shown). This is not surprising even though in apparent contradiction with the 
observed reduced apoptotic index of the N-C tumours, since in vitro stabilization of 
tumour cells involves the selection of cells able to survive and can thus mask original 
features. In contrast, marked differences in cell morphology and cell contacts 
organization were evident. All WT cell lines displayed a well differentiated epithelial 
phenotype, growing in tight islets with well organised and continuous adherent and 
tight junctions, as shown by staining of E-Cadherin, β-Catenin and Zonula occludens-
1 (Zo-1) (Fig. 1B). Accordingly, actin fibres were mainly located in the cortical 
region. In contrast, despite similar expression levels detected by Western blot (not 
shown), all C cell lines displayed discontinuous E-Cadherin, β-Catenin and Zo-1 
distribution, reduced cortical actin and evident actin stress-fibres, never detected in 
the WT cells (Fig. 1B). 
Migration and extra-cellular matrix invasion of the C and WT cell lines were 
assessed by Transwell assays with or without a Matrigel coating (Fig. 2A). Migration 
was at least doubled in all C cell lines (p=0.0013), which also showed significantly 
enhanced Matrigel invasion potential (p=0.03), suggesting higher invasive and 
metastatic activity. In order to evaluate these parameters in vivo, C1 or WT1 cells 
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were injected intravenously into nude mice and the formation of lung metastases was 
assessed after three or five weeks of injection. C1 cells produced significantly more 
and faster growing lung metastases (Fig. 2B). Similar results were obtained with the 
other cell lines (not shown). C1 cells were also able to produce subcutaneous tumours 
displaying fast and regular growth and reaching 10 mm diameter after five weeks, 
while tumours produced by the WT1 cells grew much slower and never reached the 
10 mm size (not shown). 
 
Cten is a novel STAT3 target gene partly mediating cell contacts disruption and 
enhanced migration.  
Gene expression profiles of all cell lines were compared using an Illumina microarray 
platform. The rank products function  was used to produce a list of 23 up-regulated 
genes, most of which functionally related to growth control and/or tumour biology 
(10). Consistent differential expression was confirmed for Cten/tensin 4, Galectin 3 
(Lgals3), Twist1, Lypd3 (ly6/Plaur domain containing 3) and Proliferin 2. In addition, 
both Cten and Twist 1 also displayed significantly higher expression in the N-C 
tumours as compared to their N-WT controls (not shown). 	  
Cten, the most consistently up-regulated gene, has been shown to be implicated in 
EGF-dependent mammary cell migration (12). We therefore decided to assess its 
contribution to the observed phenotype of the C cell lines. siRNA treatment could 
efficiently reduce Cten levels to about 20% in both the C1 and C2 cell lines (not 
shown), resulting in significant inhibition of cell migration (Fig. 3A) and, 
intriguingly, in partial reversion of both Zo-1 and β-Catenin cell surface distribution 
(Fig. 3B). Cells adopted a more epithelial phenotype and displayed enhanced and 
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more continuous cortical localization of both epithelial markers, correlating with 
tighter cell-cell contacts as already evident in the phase-contrast images. 
Both Cten overexpression and increased cell migration were indeed dependent on 
Stat3 activity, since treatment of C1 cells with the specific Stat3 inhibitor S3I  
coordinately and strongly reduced Stat3 phosphorylation, Cten levels and cell 
migration (Fig. 3C). In addition, we observed that IL-6 treatment could efficiently 
upregulate CTEN in MCF10 human mammary cells in a STAT3-dependent manner 
(10).  
 
STAT3 constitutive activation elicits pre-oncogenic features in Stat3C/C MEFs. 
We sought then to assess whether primary Stat3C/C MEFs displayed pre-oncogenic or 
transformed features (11). Stat3C/C cells grew faster than their wild type controls and 
displayed an accelerated cell cycle, with a more rapid transit through S-phase (not 
shown). Even though growing in monolayer, they reached higher cell density at 
confluence and were highly resistant to apoptosis induced by different stimuli such as  
H2O2 treatment (20% of apoptotic cells after 16 hours, compared to 85% in the wild 
type controls, Figure 4A), serum starvation and UV treatment (11). Moreover, 
Stat3C/C cells showed a strong delay in spontaneous senescence, as shown by beta-
galactosidase staining three and six weeks post-confluence (Figure 4B). While by six 
weeks all Stat3WT/WT cells were dead, Stat3C/C cells started to show β-gal positivity but 
were able to survive and resume proliferation when passaged.  
 
Stat3C induces a metabolic switch to aerobic glycolysis in primary MEFs. 
Gene expression profiling revealed about 1000 differentially expressed genes between 
Stat3C/C and Stat3WT/WT MEFs. Many of the down-regulated genes in the Stat3C/C cells 
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belonged to gene ontology (GO) categories related to mitochondrial function (not 
shown). Conversely, several genes involved in glycolysis were highly expressed in 
the Stat3C/C cells, including the hypoxia inducible factor (Hif)-1α and the pyruvate 
dehydrogenase kinase (Pdk)-1, the glucose transporter Glut-1 and two key enzymes, 
phospho-fruktokinase L-type (Pfk-L) and enolase-1 (Eno-1), all known HIF-1α target 
genes (Figure 5A). Accordingly, Stat3C/C cells exhibited a glycolytic phenotype, 
producing higher amounts of lactate and consuming more glucose (Figure 5B), and 
they were highly sensitive to glucose deprivation as compared to their wild type 
controls, as shown both by cultivating cells in glucose-free medium and by treatment 
with the glucose analog 2-DG (11). 
Hif-1α silencing normalized the glycolytic metabolism of Stat3C/C MEFs, leading to 
down-regulation of Pdk-1, Glut-1, Pfk-L and Eno-1 mRNAs but not of the glycolysis-
unrelated STAT3 target Socs3 (Figure 5C). Accordingly, lactate production, glucose 
intake and sensitivity to glucose deprivation were strongly reduced (Figure 5D and 
not shown). Thus, the expression of STAT3C, which mimics the constitutive STAT3 
activation observed in many tumours, is sufficient to promote aerobic glycolysis, 
acting at least in part through transcriptional induction of HIF-1α.  
 
Reduced mitochondrial activity in Stat3C/C MEFs. 
Stat3C/C MEFs showed a significant down-regulation of nuclear-encoded genes 
involved in mitochondrial function, correlating with reduced protein levels of 
representative components of the Electron Transport Chain (ETC), particularly those 
belonging to complexes IV and V (Figure 6A). This observation suggests potentially 
reduced cellular respiration, similar to what observed in cancer cells displaying 
aerobic glycolysis and the Warburg effect. We thus assessed both mitochondrial-
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specific Ca2+ uptake, which directly regulates oxidative phosphorylation, and 
mitochondrial ATP production. Stat3C/C MEFs indeed showed reduced mitochondrial 
Ca2+ uptake upon ATP stimulation (Figure 6B). Accordingly, both mitochondrial ATP 
production and basal respiratory chain activity were reduced (Figures 6C and 6D), 
correlating with lowered maximal respiratory chain activity, measured in the 
uncoupled state (Figures 6E). Importantly, the reduced mitochondrial activity was 
STAT3-dependent, but could not be rescued by Hif-1α silencing (not shown), 
suggesting that constitutively active STAT3 regulates aerobic glycolysis and cellular 
respiration via two distinct mechanisms. 
 
STAT3-dependent glycolysis contributes to in vitro and in vivo survival of cancer 
cell lines addicted to STAT3 activity. 
Our data suggest that constitutively active STAT3 can act as a central mediator of 
aerobic glycolysis, which would explain the general STAT3 addiction of cancer cells. 
To test this idea, we assessed the effects of inhibiting STAT3 on the glycolytic 
metabolism and mitochondrial activity of the STAT3-dependent epithelial tumour cell 
line MDA-MB468. Inhibition of STAT3 activity with the S3I compound dramatically 
lowered Hif-1α and Pdk-1 expression and decreased lactate production (Figure 7A), 
at the same time rescuing mitochondrial-Ca2+ uptake (Figure 7B). Similar 
observations were obtained with other two STAT3-dependent cell lines (DU145 and 
SKBR3), while STAT3 inhibition did not have any effects on the control cancer cell 
line T47D, which does not display constitutive STAT3 activity and, accordingly, does 
not depend on STAT3 for survival (data not shown). Thus, tumour cell lines which 
display constitutive STAT3 Y-P and are dependent on STAT3 for survival exhibit a 
strictly STAT3-dependent aerobic glycolytic phenotype, comparable to that observed 
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in the Stat3C/C MEFs.  
To confirm the fundamental role of STAT3 in regulating the glycolytic switch of 
STAT3-dependent tumour cells in vivo, we measured the glucose uptake of 
xenografted MDA-MB468 tumours in the presence or absence of S3I treatment by 
means of PET analysis, using the radioactive glucose-analogue 18F-FDG (PET-FDG, 
Figure 7C). S3I treatment was started when the tumours had reached the volume of 60 
mm3 (day 0). Tumours of untreated mice continued to grow, displaying increasingly 
high ratios between glucose uptake and tumour volume (Figure 7D). In contrast, 
tumour growth in S3I-treated mice was arrested already after three days of treatment, 
while the glucose uptake:tumour volume ratio decreased, suggesting that STAT3 
addiction in these cancer cells is based at least partly on STAT3-dependent aerobic 
glycolysis.   
 
Discussion 
 
The addiction to STAT3 constitutive activity observed in many tumours of distinct 
origin, where distinct patterns of target genes are induced, suggests that tumour cells 
rely on STAT3 transcriptional activity for some fundamental biological function 
shared by most tumours. Additionally, STAT3 constitutive activity is often observed 
in sites of chronic inflammation as a result of localized production of IL-6, where it 
triggers the onset of inflammation-related cancer, often in conjunction with the 
transcription factor NF-kB (9). Thus, STAT3 appears to act at different levels during 
tumorigenesis, i.e. i) altering the activity of the pre-tumoral niche, ii) favouring 
survival and abnormal proliferation during the transformation process and iii) 
enhancing the invasive and metastatic potential of  fully transformed tumour cells.  
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Our data show indeed that constitutively active STAT3 can enhance breast 
tumorigenesis downstream of the Neu oncogene via protection from apoptosis and 
promotion of tumour aggressiveness and metastasis. Interestingly, dissection of the 
latter indicates that in the C and WT tumour-derived cell lines the aggressive 
phenotype could correlate with disrupted distribution of adherent and tight junctions, 
loss of cortical actin and development of actin stress fibres, mediated for a good part 
by the newly identified STAT3 target Cten (13). Cten is known to mediate EGF-
induced migration (12), to promote cell motility of colon and pancreas cancer cells, 
and to be overexpressed in late stage epithelial tumours of different kind, often 
correlating with STAT3 constitutive activity (14). CTEN expression is particularly 
elevated in the highly aggressive and invasive inflammatory breast cancers, together 
with high EGFR and HER2 levels, loss of oestrogen receptor and lymph node 
metastasis (12). Thus our observation of STAT3-mediated CTEN induction by IL-6 
suggests that this tensin may be an important mediator in the loop inflammation - 
STAT3 - migration/metastasis, representing a point of convergence with altered 
EGFR and/or HER2-mediated signalling, both of which can trigger STAT3 activation.  
On the other hand, we also show that constitutive STAT3 activity is sufficient to 
trigger the switch to aerobic glycolysis. This property can explain why so many 
biologically distinct tumours are addicted to STAT3 activity for continuous survival 
and growth. Indeed, most cancer cells share the feature of producing ATP mainly 
through aerobic glycolysis -the Warburg effect-, thus becoming addicted to high 
glucose influxes (15). Moreover, enhanced aerobic glycolysis can per se favour 
tumoral transformation. The central role of STAT3 in orchestrating this metabolic 
switch is corroborated by the observation that several STAT3-dependent tumour cell 
lines display high aerobic glycolysis mediated by STAT3 activity. STAT3 addiction 
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in these cells is indeed linked to STAT3-induced glycolysis, as suggested by the 
observation that its inhibition down-regulates the glycolysis rate while up-regulating 
mitochondrial activity prior to leading to apoptotic cell death. Importantly, our data 
with tumour xenografts support the idea that STAT3 addiction occurs via the same 
mechanism also in vivo (11).  
The mechanism of this STAT3-dependent metabolic switch appears to be twofold. On 
one side aerobic glycolysis is due to the low level induction of Hif-1α mRNA (and 
protein) mediated by continuous STAT3 activation. This sustained induction is likely 
to represent an important functional difference between acute and constitutive STAT3 
activity and to allow fast proliferation (16). On the other hand, the down-regulation of 
mitochondrial activity is HIF-1α-independent, and likely caused by the observed 
STAT3-dependent down-regulation of nuclear genes encoding for mitochondrial 
proteins, leading to reduced levels of ETC components. The reduced mitochondrial 
activity may contribute to the decreased ROS accumulation observed in the Stat3C/C 
MEFs (11), which in turn is likely to trigger the high resistance of these cells to 
apoptosis and senescence, two hallmarks of cellular transformation. Although Stat3C/C 
MEFs are not transformed, they present features of cells undergone a first hit in the 
multi-step transformation process, as suggested by preliminary experiments with 
spontaneous immortalization (M.D. and V.P., manuscript in preparation).  
In conclusion, we show here that STAT3, found constitutively active in the pre-
tumoral niche, can induce a metabolic switch which predisposes cells to aberrant 
survival, enhanced proliferation and finally tumour transformation. Moreover, 
enhanced IL-6-induced Cten expression later contributes to tissue infiltration and 
metastasis. While not excluding of course the contribution of many other tumour-
specific STAT3 target genes, we believe that this represents a unifying view 
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explaining several of the pro-oncogenic activities of this multi-faceted transcription 
factor.  
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Materials and Methods 
Animals, treatments and analysis. Mice were maintained in the transgenic unit of 
the Molecular Biotechnology Center (University of Turin) under a 12 hour light-dark 
cycle and provided food and water ad libitum. Procedures were conducted in 
conformity with national and international laws and policies as approved by the 
Faculty Ethical Committee. The generation of the N-C mice and the analysis of 
tumour onset was described (10). 
Cell lines: Tumour cell lines were isolated from three different N-C and N-WT mice 
and cultured in complete medium as described (10). MEFs were prepared from 13.5 
days embryos. Both MEFs and MDA-MB468 (ATCC, Manassas VA, USA) were 
grown as described (11). S3I-201 inhibitor was used at a concentration of 100 µM 
(MEFs and MDA-MB468) or 200 µM (C1 cells). Transwell invasion and migration 
assays were performed as described (10). 
Lung metastasis. 1x105 cells were injected into the tail vein of nude CD1 female 
mice. Mice were sacrificed after 3 weeks and the lungs fixed as described (10). 
Semiserial sections at 100 µm intervals were stained with H&E and neoplastic lesions 
counted in blind.  
Cten silencing. Cells were plated at a density of 60% and incubated for 72 hours with 
1µM Accell SMARTpool siRNA (E-054907-00) or with the Accell Non-Targeting 
siRNA (D-001910-01-05, Dharmacon, Thermo Fisher Scientific Lafayette CO, USA) 
according to manufacturer’s protocol. 
Immunofluorescence. Immunofluorescence was performed as previously described 
(10) and imaged with an Axiovert 200M Zeiss microscope or an Axio-Observer-Z1 
Zeiss microscope with the ApoTome system for optical sectioning. 
In vitro cell death and senescence assay. Cell death: cells were treated with H2O2 
(Sigma Aldrich, 1 mM for 16 hours) followed by staining with Annexin-V. 
Senescence: cells were stained at the indicated times after plating using a Senescence 
Cells Histochemical Staining Kit (Sigma Aldrich), according to manufacturer’s 
protocol.  
Real Time-PCR. Total RNA was prepared with the PureLink Micro-to-Midi total 
RNA Purification System (Invitrogen). qRT-PCR reactions were performed as 
previously described (17), using the Universal Probe Library system (Roche Italia, 
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Monza, Italy). The 18S rRNA pre-developed TaqMan assay (Applied Biosystems) 
was used as an internal control. 
Glucose and lactate measurements. Glucose or lactate were measured in cell 
supernatants 3 hours after fluid replacement using a Glucose Assay Kit (Sigma 
Aldrich) or a Lactate Colorimetric Assay Kit (Abcam). Data were normalized to cell 
counts. 
Lentiviral infection. pLKO vectors carrying either scrambled or shRNA-Hif-1α 
sequences (Open Biosystems, Huntsville AL, USA) were packaged by transfecting 
293T cells and used to infect cells for 24 hours, followed by puromycin selection for 
48 hours. 
Calcium and ATP measurements. Cells were grown on glass coverslips at 50% 
confluence. For Ca2+ measurements,  cells were infected with the adenovirus 
expressing the appropriate aequorin chimera and the light signal was collected and 
calibrated into [Ca2+] values, as previously described (11). For measuring 
mitochondrial ATP, MEFs were transfected with mitochondrial luciferase (mtLuc), 
and luminescence measured after 36 hours as described (11).  
Respiratory chain activity. MEFs grown in 24-well plates were washed with PBS, 
PBS containing 5 mM glucose and 6 µM resazurine was added and fluorescence was 
recorded immediately in a microplate reader (Infinite M200, Tecan, Austria) at 510 
nm excitation and 595 nm emission wavelengths. For control of the threshold 
activity, cells were preincubated for 15 min with 2 µM KCN in complete medium 
and measurements were performed as described above but in PBS containing 2 µM 
KCN. The activity values were normalized to mg of protein. 
Small animal PET. PET images were acquired on the positron emission tomograph 
for small animals YAP-(S)PET system as described (11). Briefly, mice were 
anesthetized by inhalation of 2% of isofluorane and intravenously injected with 
350µCi±50 of [18F]fluorodeoxyglucose ([18F]FDG) in a 0.15-ml volume. 
Quantitative image analysis of tracer uptake was evaluated by drawing region of 
interest (ROI) of tumour on the transaxial images. [18F]FDG uptake was quantified as 
standardized uptake values (SUV) and as percentage of the injected dose per gram of 
tissue (%ID/g). 
Statistical analysis. Kaplan-Meier survival curves were analyzed by Prism4 
(GraphPad software); p values were calculated using the long-rank test. All other p 
values were calculated using Student’s t test (unpaired, two tailed).
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Figure Legends 
 
Figure 1. Stat3C enhances Neu-mediated mammary gland tumorigenesis. (A) 
Kaplan-Meier curve showing the percentage of N-WT (n=20) or N-C (n=24) female 
mice free of palpable tumours as a function of age (p=0.0014). (B) The C1 and WT1 
tumour-derived cell lines were plated on coated glass slides and incubated with 
phalloidin-TRITC or with antibodies against E-Cadherin, β-Catenin (mouse 
monoclonal) or Zo-1 (rabbit polyclonal) followed by Hoechst staining and incubation 
with FITC-labelled anti-mouse or TRITC-labelled anti-rabbit antibodies. Modified 
from reference (10). 
 
Figure 2. The C cell lines display increased invasivity both in vitro and in vivo. (A) 
the indicated tumour-derived cell lines were subjected to Transwell migration assay 
(top) or to Matrigel invasion assay (bottom) in response to FCS. The histograms (C, 
blue bars; WT, red bars) show the mean number±SEM of migrated cells per 
microscopic field (20X, p=0.0013), or the mean number±SEM of invading cells per 
Transwell insert expressed as a percentage of the value obtained with WT1 stimulated 
cells (p=0.003). One representative experiment out of three independently performed 
in triplicate is shown in each case. (B) In vivo tumorigenesis. 1x105 WT1 or C1 cells 
were injected in the tail vein of nude mice (n=4). Lungs were dissected 3 weeks after 
injection and fixed, sectioned and stained with H&E (Scale bar=1 mm). The mean 
number of metastases per lung is shown. Modified from reference (10). 
 
Figure 3. Cten silencing partially reverts the aggressive phenotype of C cells. (A, B) 
C1 cells were treated for 72 hours with the SMARTpool siRNA reagent (Accell 
system, Dharmacon) against Cten (si-Cten) or with a control Accell non-targeting 
siRNA (si-ctr) and subjected to a Transwell migration assay in response to FCS (A) or 
to immunofluorescence staining (B). (A) Values are shown as mean numbers±SEM of 
migrated cells per microscopic field (20X) of triplicates in one representative 
experiment out of two independently performed (p<0,05). (B) Phase contrast and 
immunofluorescence images of silenced C1 cells from (A). Arrows in the phase 
contrast images indicate particularly evident discontinuous (si-ctr) versus tight (si-
Cten) cell-cell contacts. Nuclei are shown in blue, β-Catenin in green, Zo-1 in red. 
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The areas indicated by an asterisk in the phase contrast images are magnified in the 
insets (4x magnification). Scale bar = 20 µm. (C) C1 cells were treated or not with the 
Stat3-specific inhibitor S3I for 10 or 48 h and analyzed by Western blot with the 
indicated antibodies (top) or treated for 48 h, followed by Transwell migration assay 
in response to FCS (bottom). Modified from reference (10). 
 
Figure 4. Phenotype of the Stat3C/C MEFs. Primary MEFs were derived from Stat3C/C 
or Stat3WT/WT embryos and experiments performed on at least three independent 
samples per genotype. (A) Apoptosis protection. Cells were treated with H2O2 for 16 
hours, photographed in phase contrast and stained with Annexin V. Numbers 
represent the percentage±SEM of Annexin V positive cells. (B) Delayed senescence. 
β-galactosidase activity assessed at 3 and 6 weeks post-confluence. Stat3WT/WT cells 
were all dead at 6 weeks. Modified from reference (11). 
 
Figure 5. HIF-1α dependent glycolytic metabolism of Stat3C/C MEFs. The histograms 
represent mean values±SEM of three independent experiments. *p ≤ 0.01. (A) 
Taqman RT-PCR quantification of HIF-1α, hypoxia-inducible factor-1α; PDK-1, 
pyruvate dehydrogenase kinase-1; GLUT-1, glucose transporter-1; PFK-L, phospho-
fruktokinase-liver type; ENO-1, enolase-1. (B) Lactate production was measured in 
the culture medium as a function of concentration, time and cell number. Glucose 
intake was calculated as the difference in glucose concentration in the medium before 
and after cell culturing. Taqman RT-PCR quantification of the indicated mRNAs (C), 
lactate production and glucose intake (D) were measured in cells either silenced or not 
for HIF-1α (sh-Hif-1a). Modified from reference (11). 
 
Figure 6. Decreased mitochondrial activity of Stat3C/C MEFs. (A) Mitochondrial 
complexes were quantificated by Western blot. The following antibodies against 
specific ETC components were used: CI subunit NDUFB8, complex I; CII-30kD, 
complex II; CIII-Core protein, complex III; CIV subunit, complex IV; CV alpha 
subunit, complex V. Actin and SOD2 were used as internal controls for total and 
mitochondrial content, respectively. (B) Mitochondrial Ca2+ homeostasis. MEFs of 
the indicated genotypes were transduced with a mitochondria-targeted aequorin 
construct, light emission was measured upon challenging with 100 µM ATP as 
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indicated. (C) ATP–induced changes in ATP concentration in mitochondria. MEFs 
were transiently transfected with a mitochondria-targeted luciferase construct 36 
hours prior to ATP stimulation and luciferase measurement. Data are expressed as a 
percentage of the initial value. (D) Respiratory chain activity measured with 
resazurine. (E) Maximal respiratory chain activity, measured with the use of 
resazurine in the presence of 300 nM FCCP. *p < 0.01. Modified from reference (11). 
 
Figure 7 In vitro and in vivo STAT3-dependent glycolytic metabolism in MDA-
MB468 human breast tumour cells. (A) Expression of the indicated mRNAs and 
lactate production were measured in MDA-MB468 cells, either treated or not with the 
S3I STAT3 inhibitor for 12 hours. (B) The mitochondrial Ca2+ response was assessed 
as described in the legend to Figure 6, in cells either treated or not with S3I for 12 
hours. (C) Tumour 18F-FDG uptake. Inoculated MDA-MB468 tumours were left to 
grow up to 60 mm3 prior to S3I treatment, followed after 3 and 8 days by 18F-FDG 
injection. Images were acquired at the indicated times after the first S3I treatment. 
Shown are tumour coronal section of one (out of five) S3I-treated (8 days) and one 
(out of three) control mice. Yellow arrows indicate the tumours. (D) Left, mean 
tumour volume±SEM at 3 and 8 days after S3I treatment. Right, variation of glucose 
uptake normalized over tumour size at the indicated times. % of 18F-FDG uptake= 
(Suvd=n - Suvd=0)*100/ Suvd=0. Modified from reference (11). 
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